- Home
- PSTV vs CVKD Comparison
PSTV vs CVKD Comparison
Compare PSTV & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- CVKD
- Stock Information
- Founded
- PSTV 1996
- CVKD 2022
- Country
- PSTV United States
- CVKD United States
- Employees
- PSTV N/A
- CVKD N/A
- Industry
- PSTV Medical/Dental Instruments
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- PSTV Health Care
- CVKD Health Care
- Exchange
- PSTV Nasdaq
- CVKD Nasdaq
- Market Cap
- PSTV 10.4M
- CVKD 29.5M
- IPO Year
- PSTV N/A
- CVKD 2023
- Fundamental
- Price
- PSTV $0.31
- CVKD $11.47
- Analyst Decision
- PSTV Strong Buy
- CVKD Strong Buy
- Analyst Count
- PSTV 3
- CVKD 1
- Target Price
- PSTV $10.83
- CVKD $32.00
- AVG Volume (30 Days)
- PSTV 59.8M
- CVKD 33.0K
- Earning Date
- PSTV 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- PSTV N/A
- CVKD N/A
- EPS Growth
- PSTV N/A
- CVKD N/A
- EPS
- PSTV N/A
- CVKD N/A
- Revenue
- PSTV $5,206,000.00
- CVKD N/A
- Revenue This Year
- PSTV $13.26
- CVKD N/A
- Revenue Next Year
- PSTV $8.84
- CVKD N/A
- P/E Ratio
- PSTV N/A
- CVKD N/A
- Revenue Growth
- PSTV N/A
- CVKD N/A
- 52 Week Low
- PSTV $0.16
- CVKD $5.70
- 52 Week High
- PSTV $2.31
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- PSTV 46.79
- CVKD 40.38
- Support Level
- PSTV $0.30
- CVKD $10.02
- Resistance Level
- PSTV $0.37
- CVKD $13.71
- Average True Range (ATR)
- PSTV 0.05
- CVKD 1.08
- MACD
- PSTV 0.02
- CVKD -0.13
- Stochastic Oscillator
- PSTV 53.61
- CVKD 29.72
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.